查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
原发性免疫力缺乏治疗市场规模、份额和成长分析（按适应症、药物类别、给药途径、年龄层、分销管道和地区划分）—产业预测（2026-2033 年）
市场调查报告书
商品编码
1900581

原发性免疫力缺乏治疗市场规模、份额和成长分析（按适应症、药物类别、给药途径、年龄层、分销管道和地区划分）—产业预测（2026-2033 年）

Primary Immunodeficiency Therapeutics Market Size, Share, and Growth Analysis, By Indication, By Drug Class, By Route of Administration, By Age Group, By Distribution Channel, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 186 Pages | 商品交期: 3-5个工作天内

价格
简介目录

全球原发性免疫力缺乏疾病治疗市场预计到 2024 年将达到 29.6 亿美元，到 2025 年将达到 31.3 亿美元，到 2033 年将达到 48.7 亿美元，预测期（2026-2033 年）的复合年增长率为 5.7%。

全球原发性免疫力缺乏（PI）治疗市场正稳步成长，这主要得益于公众意识的提高、诊断技术的进步以及个人化治疗方法的广泛应用。原发性免疫力缺乏涵盖约450种罕见慢性疾病，这些疾病是由影响免疫系统抵抗感染能力的基因缺陷所引起。基因技术的进步和先进的筛检方法使得早期诊断成为可能，从而推动了对免疫球蛋白替代疗法、生物目标和造血干细胞移植等长期治疗的需求。北美和欧洲的监管机构日益关注罕见疾病药物的研发，促使对新型治疗方法的投资不断增加。此外，患者权益倡导组织和官民合作关係的共同努力正在改善治疗的可及性和医疗质量，尤其是在新兴市场。

推动全球原发性免疫力缺乏治疗市场发展的因素

近年来，诊断技术的创新，包括次世代定序和基因筛检，显着缩短了原发性免疫力缺乏疾病（PI）的诊断时间。快速诊断使得治疗能够更早启动，进而减少感染疾病相关併发症，改善治疗效果。诊断准确性的提高有助于有效管理PI，增强患者的治疗依从性，并最终改善患者的整体生活品质。技术和患者照护的这些进步正在推动对原发性免疫力缺乏疾病治疗的需求成长，并促进全球相关疗法市场的发展。

限制全球原发性免疫力缺乏治疗市场发展的因素

全球原发性免疫力缺乏治疗市场面临的一大挑战是免疫球蛋白、基因疗法和干细胞疗法的高成本。这些成本限制了治疗的可及性，尤其是在低收入国家，并限制了患者获得这些至关重要且可能挽救生命的治疗的机会。此外，血浆采集成本的不断上涨也推高了免疫球蛋白疗法的整体成本，这一趋势同样影响已开发国家。这些经济障碍往往导致保险报销困难，阻碍了患者获得治疗，并增加了医疗系统有效建立和维持长期治疗计画的能力。

全球原发性免疫力缺乏治疗药物市场趋势

全球原发性免疫力缺乏治疗市场正经历人工智慧（AI）融入治疗通讯协定的显着趋势，尤其是在个人化免疫球蛋白给药方面。 AI驱动的给药演算法透过基于患者体重、感染频率和代谢率等关键因素制定个人化治疗方案，正在变革患者照护。这项创新不仅提高了治疗依从性，还最大限度地降低了给药不足和过量的风险，从而优化了资源利用。正在进行的临床检验正在验证AI在不同患者群体中的有效性，进一步加速了原发性免疫力缺乏领域精准医疗的发展。这反映了整个行业向个人化医疗解决方案的转变。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二手资料和一手资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态与展望

  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数（2025）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析

全球原发性免疫力缺乏缺陷疾病治疗市场规模（按适应症和复合年增长率划分）（2026-2033 年）

  • 通用变异型免疫力缺乏症（CVID）
  • X连锁无丙种球蛋白血症（XLA）
  • 重症联合免疫力缺乏症（SCID）
  • 威斯科特-奥尔德里奇症候群（WAS）
  • 高IgM症候群（HIGM）

全球原发性免疫力缺乏治疗药物市场规模（按药物类别划分）及复合年增长率（2026-2033 年）

  • 免疫球蛋白替代疗法
  • 免疫调节剂
  • 干细胞疗法
  • 基因治疗
  • 抗生素

全球原发性免疫力缺乏治疗药物市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

  • 静脉注射（IV）
  • 皮下（SC）
  • 肌肉内注射（IM）

全球原发性免疫力缺乏治疗市场规模（按年龄层划分）及复合年增长率（2026-2033 年）

  • 儿童
  • 成人

全球原发性免疫力缺乏治疗药物市场规模（按分销管道划分）及复合年增长率（2026-2033 年）

  • 医院
  • 专科药房
  • 网路药房

全球原发性免疫力缺乏治疗药物市场规模及复合年增长率（2026-2033）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业的市场定位（2025 年）
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市占率分析（2025 年）
  • 主要企业公司简介
    • 公司详情
    • 产品系列分析
    • 依业务板块进行公司股票分析
    • 2023-2025年营收年比比较

主要企业简介

  • CSL Behring（USA）
  • Grifols（Spain）
  • Octapharma（Switzerland）
  • Takeda Pharmaceutical Company Limited（Japan）
  • Biotest AG（Germany）
  • ADMA Biologics（USA）
  • Bio Products Laboratory（BPL）（USA）
  • LFB SA（France）
  • Kedrion Biopharma SpA（Italy）
  • Pfizer Inc.（USA）
  • Orchard Therapeutics（UK）
  • Rocket Pharmaceuticals（USA）
  • Bluebird Bio（USA）
  • China Biologic Products Holdings（China）
  • GC Pharma（South Korea）
  • Baxter International Inc.（USA）
  • X4 Pharmaceuticals（USA）
  • Novartis AG（Switzerland）
  • Sanofi SA（France）
  • Bristol Myers Squibb（USA）

结论与建议

简介目录
Product Code: SQMIG35D2303

Global Primary Immunodeficiency Therapeutics Market size was valued at USD 2.96 Billion in 2024 and is poised to grow from USD 3.13 Billion in 2025 to USD 4.87 Billion by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).

The global primary immunodeficiency (PI) therapeutics market is witnessing steady growth, driven by increased awareness, improved diagnostic techniques, and the availability of tailored treatment options. With around 450 rare, chronic disorders categorized under primary immunodeficiencies, these conditions stem from genetic defects impacting the immune system's ability to fight infections. Advances in genetic technology and enhanced screening methods facilitate early diagnosis, boosting the demand for long-term treatments such as immunoglobulin replacement therapy, targeted biologics, and hematopoietic stem cell transplantation. Regulatory bodies in North America and Europe have shown increasing interest in orphan drug development, leading to more investment in novel therapies. Moreover, concerted efforts by patient advocacy groups and public-private partnerships are improving accessibility and care, particularly in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Primary Immunodeficiency Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Primary Immunodeficiency Therapeutics Market Segments Analysis

Global Primary Immunodeficiency Therapeutics Market is segmented by Indication, Drug Class, Route of Administration, Age Group, Distribution Channel and region. Based on Indication, the market is segmented into Common Variable Immunodeficiency (CVID), X-linked Agammaglobulinemia (XLA), Severe Combined Immunodeficiency Disorders (SCID), Wiskott-Aldrich Syndrome (WAS) and Hyper-IgM Syndrome (HIGM). Based on Drug Class, the market is segmented into Immunoglobulin Replacement Therapy, Immune-modulating Agents, Stem Cell Therapy, Gene Therapy and Antibiotics. Based on Route of Administration, the market is segmented into Intravenous (IV), Subcutaneous (SC) and Intramuscular (IM). Based on Age Group, the market is segmented into Pediatric and Adult. Based on Distribution Channel, the market is segmented into Hospitals, Specialty Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Primary Immunodeficiency Therapeutics Market

Recent innovations in diagnostic technology, including next-generation sequencing and genetic screening, have significantly reduced the time needed to diagnose primary immunodeficiency (PI) diseases. Swift diagnosis enables the prompt commencement of treatment, which in turn leads to improved therapeutic outcomes by lessening infection-related complications. Enhanced diagnostic accuracy contributes to more effective management of PI, fosters better patient adherence to treatment, and ultimately improves overall quality of life for those affected. This progression in both technology and patient care has led to a growing demand for primary immunodeficiency medications, propelling the expansion of the global market for these therapeutics.

Restraints in the Global Primary Immunodeficiency Therapeutics Market

A significant challenge facing the global primary immunodeficiency therapeutics market is the high cost associated with immunoglobulin therapy, gene therapy, and stem cell therapy. Such expenses create affordability issues, particularly in low-income countries, restricting patient access to essential treatments that could be life-saving. In addition, the rising prices of plasma collection further contribute to the overall cost of immunoglobulin treatments, a trend that is also affecting developed nations. These financial obstacles often lead to reimbursement difficulties, hindering patient access and complicating the ability of healthcare systems to establish and sustain long-term treatment programs effectively.

Market Trends of the Global Primary Immunodeficiency Therapeutics Market

The Global Primary Immunodeficiency Therapeutics market is witnessing a significant trend towards the integration of artificial intelligence in treatment protocols, particularly through individualized immunoglobulin dosing. AI-driven dose algorithms are transforming patient care by personalizing treatment regimens based on key factors like patient weight, infection frequency, and metabolic rates. This innovation not only enhances treatment adherence but also minimizes the risks of under- or overdosing, thereby optimizing resource utilization. As ongoing clinical trials seek to validate AI efficacy across diverse patient populations, the momentum for precision medicine in primary immunodeficiency is expected to gain traction, reflecting a broader industry shift towards tailored healthcare solutions.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Primary Immunodeficiency Therapeutics Market Size by ndication & CAGR (2026-2033)

  • Market Overview
  • Common Variable Immunodeficiency (CVID)
  • X-linked Agammaglobulinemia (XLA)
  • Severe Combined Immunodeficiency Disorders (SCID)
  • Wiskott-Aldrich Syndrome (WAS)
  • Hyper-IgM Syndrome (HIGM)

Global Primary Immunodeficiency Therapeutics Market Size by Drug Class & CAGR (2026-2033)

  • Market Overview
  • Immunoglobulin Replacement Therapy
  • Immune-modulating Agents
  • Stem Cell Therapy
  • Gene Therapy
  • Antibiotics

Global Primary Immunodeficiency Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Intravenous (IV)
  • Subcutaneous (SC)
  • Intramuscular (IM)

Global Primary Immunodeficiency Therapeutics Market Size by Age Group & CAGR (2026-2033)

  • Market Overview
  • Pediatric
  • Adult

Global Primary Immunodeficiency Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Specialty Pharmacies
  • Online Pharmacies

Global Primary Immunodeficiency Therapeutics Market Size & CAGR (2026-2033)

  • North America (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
    • US
    • Canada
  • Europe (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (ndication, Drug Class, Route of Administration, Age Group, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • CSL Behring (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Grifols (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Octapharma (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biotest AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ADMA Biologics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio Products Laboratory (BPL) (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • LFB SA (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kedrion Biopharma S.p.A. (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Orchard Therapeutics (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Rocket Pharmaceuticals (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bluebird Bio (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • China Biologic Products Holdings (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GC Pharma (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • X4 Pharmaceuticals (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations